New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:14 EDTENDPEndo to acquire DAVA Pharmaceuticals for $575M
Endo announced that it has reached a definitive agreement to acquire DAVA Pharmaceuticals, a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575M in cash, with additional cash consideration of up to $25M contingent on the achievement of certain sales milestones. The acquisition enhances Endo's attractive commercialization and development platform and is expected to be immediately accretive to Endo's 2014 adjusted EPS. DAVA operates a highly-profitable generics franchise with 2013 revenue of approximately $131M and 2013 adjusted EBITDA of approximately $100M. The company also expects over 5 products to be launched in 2015, and more than 20 additional products to be launched over the next several years. The transaction is subject to requisite regulatory approvals and customary closing conditions, and is expected to be completed in the second half of 2014.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTENDPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 14, 2014
09:31 EDTENDPEndo upgraded to Conviction Buy from Buy at Goldman
July 11, 2014
08:05 EDTENDPEndo recommended ahead of Q2 report at Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use